# US 2026/0060936 A1 · Indolium-based stabilizers of hydrophobic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060936 A1
- Document ID: US20260060936A1
- Status: Published application
- Kind: A1
- Application number: 19/104,171
- Filed: 2023-08-29
- Published: 2026-03-05
- Earliest claimed: 2022-08-31
- Assignees: Technion Research & Development Foundation Limited
- Applicants: Technion Research & Development Foundation Ltd.
- Inventors: Yosi SHAMAY; Yuval HARRIS; Danna NIEZNI; Hagit SASON
- Web page: https://patentgrep.com/patent/US20260060936A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61P 35/00: Antineoplastic agents
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 38/13: Cyclosporins
- A61K 38/20: Interleukins [IL]
- A61K 38/21: Interferons {[IFN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.

## Claims

### Claim 1

A composition comprising a mixture of oligomers obtained by exposing an indolium-based monomer of formula I,
wherein:
R1, R2, and R3 each independently is (C1-C6)alkyl optionally interrupted with one or more heteroatoms selected from the group consisting of O, N, and S;
R4 is (C1-C12)alkyl optionally interrupted with one or more heteroatoms selected from the group consisting of O, N, and S, substituted with one or more groups each independently selected from the group consisting of —SO3−, —COO−, —PO3−2, —OH, —NH2, —N+(R′)3, phosphocholine (—OPO3−—(CH2)2—N+(CH3)3), and acetoxyethyl phospocholine (—CH2—C(O)—O—(CH2)2—OPO3−—(CH2)2—N+(CH3)3), wherein R′ each independently is (C1-C6)alkyl, or (C3-C7)cycloalkyl, or two of the R's together with the nitrogen atom to which they are attached form a 5-9 membered ring;
R5, R6, R7, and R8 each independently is selected from the group consisting of H, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH; or two adjacent of R5, R6, R7, and R8 together with the carbon atoms to which they are attached form (C6-C14)aryl or 5- to 14-membered heteroaryl, optionally substituted by one or more groups each independently selected from the group consisting of halogen, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH, and the other of R5, R6, R7, and R8 each independently is selected from the group consisting of H, —OH, (C1-C6)alkyl, —O—(C1-C6)alkyl, —CO(C1-C6)alkyl, —COO(C1-C6)alkyl, —N(R9)2, —CON(R9)2, —S—(C1-C6)alkyl, and —SH; and
R9 each independently is H, halogen, (C1-C6)alkyl, (C3-C11)cycloalkyl, (C5-C11)cycloalkenyl, heterocyclyl, aryl, heteroaryl, or two R9's together with the nitrogen atom to which they are attach form a 5- to 7-membered ring,
optionally together with an additional monomer selected from the group consisting of dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer.

### Claim 2 (depends on 1)

The composition of claim 1, wherein R1, R2, and R3 each independently is (C1-C6)alkyl.

### Claim 3 (depends on 2)

The composition of claim 2, wherein R1, R2, and R3 are identical.

### Claim 4 (depends on 3)

The composition of claim 3, wherein R1, R2, and R3 each is methyl.

### Claim 5 (depends on 1)

The composition of claim 1, wherein R4 is (C1-C6)alkyl substituted with one or more —SO3−, phosphocholine, or acetoxyethyl phospocholine groups.

### Claim 6 (depends on 5)

The composition of claim 5, wherein R4 is a linear (C1-C6)alkyl substituted with a sole —SO3−, phosphocholine, or acetoxyethyl phospocholine group at the omega position thereof.

### Claim 7 (depends on 6)

The composition of claim 6, wherein R4 is —(CH2)4—SO3—, —(CH2)3—OPO3−—(CH2)2—N+(CH3)3, or —(CH2)4—C(O)—O—(CH2)2—OPO3−—(CH2)2—N+(CH3)3.

### Claim 8 (depends on 1)

The composition of claim 1, wherein R5, R6, R7, and R8 each independently is H, or (C1-C6)alkyl; or R5 and R6 each independently is H, or (C1-C6)alkyl, and R7 and R8 together with the carbon atoms to which they are attached form an optionally substituted (C6-C14)aryl.

### Claim 9 (depends on 8)

The composition of claim 8, wherein R7 and R8 together with the carbon atoms to which they are attached form phenyl.

### Claim 10 (depends on 1)

The composition of claim 1, wherein:
R1, R2, and R3 each independently is (C1-C6);
R4 is (C1-C6)alkyl substituted with one or more —SO3−, phosphocholine, or acetoxyethyl phospocholine groups; and
R5, R6, R7, and R8 each independently is H, or (C1-C6)alkyl; or R5 and R6 each independently is H, or (C1-C6)alkyl, and R7 and R8 together with the carbon atoms to which they are attached form an optionally substituted (C6-C14)aryl.

### Claim 11 (depends on 10)

The composition of claim 10, wherein:
R1, R2, and R3 are identical;
R4 is a linear (C1-C6)alkyl substituted with a sole —SO3−, phosphocholine, or acetoxyethyl phospocholine group at the omega position thereof; and
R7 and R8 together with the carbon atoms to which they are attached form phenyl.

### Claim 12 (depends on 11)

The composition of claim 11, wherein:
(i) R1, R2, and R3 each is methyl; R4 is —(CH2)4—SO3−; and R5, R6, R7, and R8 each is H (2,3,3-trimethyl-1-(4-sulfobutyl)indolium inner salt, also referred to herein as In783);
(ii) R1, R2, and R3 each is methyl; R4 is —(CH2)4—SO3−; R5 and R6 each is H; and R7 and R8 together with the carbon atoms to which they are attached form phenyl (1,1,2-trimethyl-3-(4-sulfobutyl)benz[e]indolium inner salt, also referred to herein as In820);
(iii) R1, R2, and R3 each is methyl; R4 is —(CH2)3—OPO3−—(CH2)2—N+(CH3)3; R5 and R6 each is H; and R7 and R8 together with the carbon atoms to which they are attached form phenyl (3-(1,1,2-trimethyl-1H-benzo[e]indol-3-ium-3-yl)propyl phosphocholine); or
(iv) R1, R2, and R3 each is methyl; R4 is —(CH2)4—C(O)—O—(CH2)2—OPO3−—(CH2)2—N+(CH3)3—; R5 and R6 each is H; and R7 and R8 together with the carbon atoms to which they are attached form phenyl (2-(2-(1,1,2-trimethyl-1H-benzo [e]indol-3-ium-3-yl)acetoxy)ethyl phosphocholine).

### Claim 13 (depends on 1)

The composition of claim 1, wherein said basic buffer is tris(hydroxymethyl)aminomethane (TRIS) buffer, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO) buffer, N-[tris(hydroxymethyl)methyl]glycine (Tricine) buffer, 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine) buffer, [tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS) buffer, a borate-based buffer, a tetraborate-based buffer, or a bicarbonate-based buffer, potassium bicarbonate buffer, ammonium bicarbonate buffer, triethylammonium bicarbonate buffer, and carbonate bicarbonate buffer.

### Claim 14 (depends on 13)

The composition of claim 13, wherein said buffer is a bicarbonate-based buffer.

### Claim 15 (depends on 1)

The composition of claim 1, wherein: (i) said indolium-based monomer has been exposed to said basic buffer at a temperature of from about 18° C. to about 150° C.; (ii) said indolium-based monomer has been exposed to said basic buffer for at least 2 hours; and/or (iii) a concentration of said indolium-based monomer is from about 1 mg/ml to about 100 mg/ml.

### Claim 16 (depends on 1)

The composition of claim 1, obtained by:
(a) exposing 1,1,2-trimethyl-3-(4-sulfobutyl) benz[e]indolium inner salt to a bicarbonate-based buffer; or
(b) exposing 1,1,2-trimethyl-3-(4-sulfobutyl) benz[e]indolium inner salt, together with an additional monomer selected from the group consisting of dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a bicarbonate-based buffer.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The composition of claim 16, wherein:
said additional monomer is dopamine, L-dopa, or a mixture thereof; or
said additional monomer is dopamine or serotonin, and a molar ratio between the 1,1,2-trimethyl-3-(4-sulfobutyl)benz[e]indolium inner salt, and said dopamine or serotonin is about 2:1, respectively.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said additional monomer is a mixture of dopamine and L-dopa, and the molar ratio between the 1,1,2-trimethyl-3-(4-sulfobutyl) benz[e]indolium inner salt, said dopamine, and said L-dopa is about 1:1:1, respectively.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The composition of claim 1, further comprising a hydrophobic substance.

### Claim 22 (depends on 21)

The composition of claim 21, in the form of (a) a suspension of nanoparticles, each comprising said mixture of oligomers and said hydrophobic substance, in an aqueous liquid; or (b) a powder.

### Claim 23 (depends on 22)

The composition of claim 22, wherein a size of said nanoparticles ranges from about 20 nm to about 400 nm.

### Claim 24

(canceled)

### Claim 25 (depends on 34)

The composition of claim 34, wherein said hydrophobic substance is a drug selected from the group consisting of an anticancer (chemotherapeutic) drug, antifungal drug, antibacterial drug, antiviral drug, immunosuppressive drug, anti-hyperlipidemic drug, nonsteroidal anti-inflammatory drug, cardiac drug, neurological drug, psychoactive drug, drug of abuse, alkaloid, antibiotic, bioactive peptide, steroid, steroid hormone, selective estrogen receptor modulator (SERM), 5-alpha reductase inhibitor, peptide hormone, interferon, interleukin, narcotic, nucleic acid, pesticide, and prostaglandin.

### Claim 26 (depends on 25)

The composition of claim 25, wherein: (i) said anticancer drug is a protein kinase inhibitor; angiogenesis and myeloma cell growth inhibitor; an antiandrogen medication; an anthracycline antibiotic; a B-cell lymphoma 2 inhibitor; a taxane-based drug; an antitumor antibiotic; a benzamide histone deacetylase inhibitor; a cancer cell stemness inhibitor; a flavagline; a Hedgehog signaling pathway targeting agent; a transforming growth factor beta (TGF-β) inhibitor; a poly ADP ribose polymerase (PARP) inhibitor; a retinoid-based drug; a topoisomerase inhibitor; an epidermal growth factor receptor (EGFR) inhibitor; a mammalian target of rapamycin (mTOR) inhibitor; a proteasome inhibitor; or a nonsteroidal antiandrogen (NSAA) medication; (ii) said antibacterial drug is a soluble adenylyl cyclase inhibitor; (iii) said anti-hyperlipidemic drug is probucol; (iv) said 5-alpha reductase inhibitor is dutasteride; (v) said nonsteroidal anti-inflammatory drug is a cyclooxygenase-2 inhibitor; (vi) said selective estrogen receptor modulator is ospemifene; or (vii) said immunosuppressive drug is a calcineurin inhibitor.

### Claim 27 (depends on 34)

The composition of claim 34, wherein said hydrophobic substance is a hydrophobic drug comprising a 2-(N-anilino)pyrimidine group coupled to π-conjugated system directly or via a nitrogen atom.

### Claim 28 (depends on 21)

The composition of claim 21, formulated for enteral administration, parenteral administration, inhalation.

### Claim at position 29

29-31. (canceled)

### Claim 32 (depends on 13)

The composition of claim 13, wherein said borate-based buffer is sodium borate; said tetraborate-based buffer is sodium tetraborate or disodium tetraborate; or said bicarbonate-based buffer is sodium bicarbonate buffer, potassium bicarbonate buffer, ammonium bicarbonate buffer, triethylammonium bicarbonate buffer, or carbonate bicarbonate buffer.

### Claim 33 (depends on 15)

The composition of claim 15, wherein: (i) said indolium-based monomer has been exposed to said basic buffer at a temperature of about 90° C.; (ii) said indolium-based monomer has been exposed to said basic buffer for from about 4 hours to about 36 hours; and/or (iii) the concentration of said indolium-based monomer is from about 2 mg/ml to about 10 mg/ml.

### Claim 34 (depends on 21)

The composition of claim 21, wherein said hydrophobic substance is a drug or a dietary supplement.

### Claim 35 (depends on 26)

The composition of claim 26, wherein: (i) said protein kinase inhibitor is selected from the group consisting of nilotinib, sorafenib, staurosporine, midostaurin, ibrutinib, trametinib, regorafenib, ponatinib, afatinib, pazopanib, rociletinib, dasatinib, ceritinib, ulixertinib, cabozantinib, nintedanib, selumetinib, thiazovivin, osimertinib, defactinib, idelalisib, taselisib, mubritinib, infigratinib, duvelisib, lapatinib, and avapritinib; said angiogenesis and myeloma cell growth inhibitor is pomalidomide; said antiandrogen medication is bicalutamide; said anthracycline antibiotic is valrubicin; said B-cell lymphoma 2 inhibitor is navitoclax; said taxane-based drug is paclitaxel or docetaxel; said antitumor antibiotic is tanespimycin; said benzamide histone deacetylase inhibitor is mocetinostat; said cancer cell stemness inhibitor is napabucasin; said flavagline is rocaglamide; said Hedgehog signaling pathway targeting agent is vismodegib; said transforming growth factor beta (TGF-β) inhibitor is galunisertib; said poly ADP ribose polymerase (PARP) inhibitor is talazoparib; said retinoid-based drug is alitretinoin; said topoisomerase inhibitor is selected from the group consisting of camptothecin, etoposide, and irinotecan; said epidermal growth factor receptor (EGFR) inhibitor is gefitinib or erlotinib; said mammalian target of rapamycin (mTOR) inhibitor is everolimus or rapamycin; said proteasome inhibitor is carfilzomib; said nonsteroidal antiandrogen (NSAA) medication is enzalutamide; said soluble adenylyl cyclase inhibitor is bithionol; said cyclooxygenase-2 inhibitor is celecoxib; or said calcineurin inhibitor is tacrolimus or cyclosporine.
